Latest filings (excl ownership)
15-12G
Securities registration termination
26 Feb 24
EFFECT
Notice of effectiveness
16 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Feb 24
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Feb 24
POS AM
Prospectus update (post-effective amendment)
14 Feb 24
8-K
Completion of Acquisition or Disposition of Assets
14 Feb 24
SC TO-T/A
Third party tender offer statement (amended)
14 Feb 24
SC 14D9/A
Tender offer solicitation (amended)
14 Feb 24
25-NSE
Exchange delisting
14 Feb 24
SC 14D9/A
Tender offer solicitation (amended)
7 Feb 24
SC TO-T/A
Third party tender offer statement (amended)
7 Feb 24
CORRESP
Correspondence with SEC
7 Feb 24
UPLOAD
Letter from SEC
2 Feb 24
UPLOAD
Letter from SEC
2 Feb 24
SC 14D9/A
Tender offer solicitation (amended)
30 Jan 24
SC TO-T/A
Third party tender offer statement (amended)
30 Jan 24
CORRESP
Correspondence with SEC
30 Jan 24
UPLOAD
Letter from SEC
22 Jan 24
UPLOAD
Letter from SEC
22 Jan 24
SC 14D9
Tender offer solicitation
10 Jan 24
SC TO-T
Third party tender offer statement
10 Jan 24
SC14D9C
Written communication relating to third party tender offer
22 Dec 23
8-K
Entry into a Material Definitive Agreement
22 Dec 23
8-K
Departure of Directors or Certain Officers
4 Dec 23
8-K
Other Events
27 Nov 23
10-Q
2023 Q3
Quarterly report
17 Nov 23
NT 10-Q
Notice of late quarterly filing
15 Nov 23
8-K
Theseus Pharmaceuticals Announces Process to Explore Strategic Alternatives
13 Nov 23
8-K
Termination of a Material Definitive Agreement
31 Oct 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Theseus Pharmaceuticals Announces Business Highlights and Reports Second Quarter 2023 Financial Results
10 Aug 23
8-K
Theseus Pharmaceuticals to Discontinue Enrollment in Phase 1/2 Study and Terminate Development of THE-630 in Patients with GIST
13 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
9 Jun 23
8-K
Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST
25 May 23
10-Q
2023 Q1
Quarterly report
11 May 23
8-K
Theseus Pharmaceuticals Announces Business Highlights and Reports First Quarter 2023 Financial Results
11 May 23
ARS
2022 FY
Annual report to shareholders
26 Apr 23
DEFA14A
Additional proxy soliciting materials
26 Apr 23
DEF 14A
Definitive proxy
26 Apr 23
PRE 14A
Preliminary proxy
14 Apr 23
Latest ownership filings
SC 13D/A
TANG CAPITAL PARTNERS LP
16 Feb 24
4
Kathy Yi
14 Feb 24
4
Steven H Stein
14 Feb 24
4
Change in insider ownership
14 Feb 24
4
DONALD J HAYDEN JR
14 Feb 24
4
CARL L GORDON
14 Feb 24
4
Iain D. Dukes
14 Feb 24
4
Bradford D. Dahms
14 Feb 24
SC 13G/A
Frazier Life Sciences Public Fund, L.P.
13 Feb 24
SC 13D/A
TANG CAPITAL PARTNERS LP
12 Jan 24
SC 13D/A
TANG CAPITAL PARTNERS LP
28 Dec 23
SC 13D/A
ORBIMED ADVISORS LLC
27 Dec 23
SC 13D/A
ORBIMED ADVISORS LLC
24 Nov 23
SC 13D/A
Foresite Capital Fund V, L.P.
24 Nov 23
SC 13D
TANG CAPITAL PARTNERS LP
24 Nov 23
4
William Shakespeare
7 Nov 23
SC 13G/A
FMR LLC
10 Aug 23
4
CARL L GORDON
19 Jul 23
4
Change in insider ownership
19 Jul 23
SC 13D/A
ORBIMED ADVISORS LLC
19 Jul 23
4
James B. Tananbaum
19 Jul 23
SC 13D/A
Foresite Capital Fund V, L.P.
19 Jul 23
4
Steven H Stein
13 Jun 23
4
Kathy Yi
13 Jun 23
4
DONALD J HAYDEN JR
13 Jun 23
4
CARL L GORDON
13 Jun 23
4
Iain D. Dukes
13 Jun 23
SC 13D/A
ORBIMED ADVISORS LLC
14 Mar 23
4
Victor Rivera
2 Mar 23
4
William Shakespeare
2 Mar 23
4
David Kerstein
2 Mar 23
4
Bradford D. Dahms
2 Mar 23
4
TIMOTHY P CLACKSON
2 Mar 23
4
William Shakespeare
21 Feb 23
4
Victor Rivera
21 Feb 23
4
David Kerstein
21 Feb 23
4
Bradford D. Dahms
21 Feb 23
4
TIMOTHY P CLACKSON
21 Feb 23
SC 13G/A
FMR LLC
9 Feb 23
SC 13G
Frazier Life Sciences Public Fund, L.P.
23 Jan 23